Stacks
Interaction Unknown
For NAD+ plus MOTS-c cycling protocols, the most sensitive outcome markers fall into three tiers: whole-blood NAD+ and circulating MOTS-c as direct compound-response signals; serum creatine kinase (CK), blood lactate clearance, and heart rate variability (HRV) as functional recovery indices; and HOMA-IR as a downstream metabolic validator. No co-administration trial has validated this panel as of 2026.
September 10, 2026
·
9 min read
Stacks
Interaction Unknown
No controlled human trial has tested retatrutide plus cagrilintide together as of 2026. The combination is mechanistically coherent because triple incretin agonism and amylin-receptor activation operate through non-overlapping satiety circuits. Every weight-loss figure cited for this pairing is extrapolated from separate monotherapy and two-compound trials. The interaction class is Single-Compound Extrapolation.
September 9, 2026
·
9 min read
Stacks
Interaction Unknown
Five metric categories best capture adherence and response for peptide stack self-experimenters in 2026: per-compound proportion of days covered (PDC), dose-timing variance score, injection-site rotation index, compound-specific biomarker response windows, and structured subjective response scoring. No single metric is sufficient — adherence metrics confirm exposure fidelity while response metrics confirm whether the mechanistic window was reached.
September 8, 2026
·
9 min read
Stacks
Interaction Unknown
Adherence-tracking data from peptide protocol apps can serve as a leading indicator of outcome-relevant completion when the app captures dose-level check-ins, the stack runs long enough for a compliance curve to form, and early-week drop patterns are compared against a validated completion threshold. The structural logic is grounded in digital-health adherence literature, though no peptide-specific RCT validates the inference chain.
September 2, 2026
·
9 min read
Stacks
Interaction Unknown
As of July 2026, Verdiva Bio's Phase 1 study of VRB-103 (oral amylin analog) plus VRB-101 (oral GLP-1 agonist) is the only registered trial explicitly testing multiple fixed dose ratios of an oral amylin/GLP-1 combination. Preclinical amylin/GLP-1 co-dosing literature consistently shows non-linear, ratio-dependent weight-loss responses — a pattern that motivates the multi-ratio Phase 1 design.
August 20, 2026
·
9 min read
Stacks
Interaction Unknown
A July 2026 rat Achilles tendon transection study found that BPC-157 and TB-500 co-administration did not clearly outperform either single-agent arm on biomechanical endpoints — load-to-failure, stiffness, and cross-sectional area. The result reveals that mechanistic non-overlap is insufficient to guarantee additive tissue-level outcomes, and that the rate-limiting repair step in Achilles tendon may not be addressable by both compounds simultaneously.
August 19, 2026
·
9 min read